Elanco Animal Health R&D Spending Growth & History (ELAN)
Elanco Animal Health's r&d spending was $368.0M for fiscal 2025.
View full Elanco Animal Health company overviewElanco Animal Health annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $368.0M | $24.0M | +6.98% |
| 2024 | 2024-12-31 | $344.0M | $17.0M | +5.20% |
| 2023 | 2023-12-31 | $327.0M | $6.0M | +1.87% |
| 2022 | 2022-12-31 | $321.0M | −$48.0M | −13.01% |
| 2021 | 2021-12-31 | $369.0M | $40.0M | +12.16% |
| 2020 | 2020-12-31 | $329.0M | $59.0M | +21.85% |
| 2019 | 2019-12-31 | $270.0M | $23.4M | +9.49% |
| 2018 | 2018-12-31 | $246.6M | −$5.1M | −2.03% |
| 2017 | 2017-12-31 | $251.7M | −$14.1M | −5.30% |
| 2016 | 2016-12-31 | $265.8M | — | — |
Elanco Animal Health quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $92.0M | $0 | 0.00% |
| Q1 2026 | 2026-03-31 | $97.0M | $3.0M | +3.19% |
| Q4 2025 | 2025-12-31 | $93.0M | $12.0M | +14.81% |
| Q3 2025 | 2025-09-30 | $89.0M | $2.0M | +2.30% |
| Q2 2025 | 2025-06-30 | $92.0M | $3.0M | +3.37% |
| Q1 2025 | 2025-03-31 | $94.0M | $7.0M | +8.05% |
| Q4 2024 | 2024-12-31 | $81.0M | $2.0M | +2.53% |
| Q3 2024 | 2024-09-30 | $87.0M | $1.0M | +1.16% |
| Q2 2024 | 2024-06-30 | $89.0M | $8.0M | +9.88% |
| Q1 2024 | 2024-03-31 | $87.0M | $6.0M | +7.41% |
| Q4 2023 | 2023-12-31 | $79.0M | −$1.0M | −1.25% |
| Q3 2023 | 2023-09-30 | $86.0M | $8.0M | +10.26% |
| Q2 2023 | 2023-06-30 | $81.0M | −$1.0M | −1.22% |
| Q1 2023 | 2023-03-31 | $81.0M | $0 | 0.00% |
| Q4 2022 | 2022-12-31 | $80.0M | −$12.0M | −13.04% |
| Q3 2022 | 2022-09-30 | $78.0M | −$16.0M | −17.02% |
| Q2 2022 | 2022-06-30 | $82.0M | −$12.0M | −12.77% |
| Q1 2022 | 2022-03-31 | $81.0M | −$8.0M | −8.99% |
| Q4 2021 | 2021-12-31 | $92.0M | −$23.0M | −20.00% |
| Q3 2021 | 2021-09-30 | $94.0M | $6.0M | +6.82% |
| Q2 2021 | 2021-06-30 | $94.0M | $35.0M | +59.32% |
| Q1 2021 | 2021-03-31 | $89.0M | $22.0M | +32.84% |
| Q4 2020 | 2020-12-31 | $115.0M | $47.8M | +71.13% |
| Q3 2020 | 2020-09-30 | $88.0M | $18.1M | +25.89% |
| Q2 2020 | 2020-06-30 | $59.0M | −$9.8M | −14.24% |
| Q1 2020 | 2020-03-31 | $67.0M | $2.9M | +4.52% |
| Q4 2019 | 2019-12-31 | $67.2M | $6.1M | +9.98% |
| Q3 2019 | 2019-09-30 | $69.9M | $11.0M | +18.68% |
| Q2 2019 | 2019-06-30 | $68.8M | $7.4M | +12.05% |
| Q1 2019 | 2019-03-31 | $64.1M | −$1.1M | −1.69% |
| Q4 2018 | 2018-12-31 | $61.1M | — | — |
| Q3 2018 | 2018-09-30 | $58.9M | −$3.0M | −4.85% |
| Q2 2018 | 2018-06-30 | $61.4M | — | — |
| Q1 2018 | 2018-03-31 | $65.2M | — | — |
| Q3 2017 | 2017-09-30 | $61.9M | — | — |
Elanco Animal Health r&d spending trends
Over the last five fiscal years, Elanco Animal Health's r&d spending increased from $329.0M to $368.0M, a change of $39.0M. The latest reported quarter, Q2 2026, shows $92.0M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Elanco Animal Health source filings ↗